Evidence map›Paper›PMID 27936030›Full record

ArticlePloS one2016

Novel Methods to Generate Active Ingredients-Enriched Ashwagandha Leaves and Extracts.

Sunil C Kaul, Yoshiyuki Ishida, Kazuya Tamura, Teruo Wada, Tomoko Iitsuka, Sukant Garg, Mijung Kim, Ran Gao, Shoichi Nakai, Youji Okamoto and 2 more

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Nutraceutical Applications ofFoods (Basel, Switzerland) · 2026
    Review
  6. Extraction of Bioactive Compounds FromInternational journal of food science · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Liver Dangers of Herbal Products: A Case Report of Ashwagandha-Induced Liver Injury.International journal of environmental research and public health · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Effects ofCurrent neuropharmacology · 2021
    Review
  17. Withanone fromDrug design, development and therapy · 2021
    Article
  18. Wild type p53 function in p53Journal of experimental & clinical cancer research : CR · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sunil C KaulDrug Discovery and Assets Innovation Laboratory, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, Japan.
Yoshiyuki IshidaCycloChem Co., Ltd., 7-4-5 Minatojima-minamimachi, Chuo-ku, Kobe, Japan.
Kazuya TamuraDAI-DAN Co., Ltd., 390 Kitanagai, Miyoshi-machi, Iruma-gun, Saitama, Japan.
Teruo WadaOsaka Prefecture University, 1-1 Nakakugakuencho, Sakai-city, Osaka, Japan.
Tomoko IitsukaDrug Discovery and Assets Innovation Laboratory, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, Japan.
Sukant GargDrug Discovery and Assets Innovation Laboratory, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, Japan.
Mijung KimDrug Discovery and Assets Innovation Laboratory, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, Japan.
Ran GaoDrug Discovery and Assets Innovation Laboratory, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, Japan.
Shoichi NakaiDAI-DAN Co., Ltd., 390 Kitanagai, Miyoshi-machi, Iruma-gun, Saitama, Japan.
Youji OkamotoZuiron Private Ltd., 2-3-1 Nakajyosanjimacho, Tokushima-city, Tokushima, Japan.
Keiji TeraoCycloChem Co., Ltd., 7-4-5 Minatojima-minamimachi, Chuo-ku, Kobe, Japan.
Renu WadhwaDrug Discovery and Assets Innovation Laboratory, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ashwagandha (Withania somnifera) is an Ayurvedic herb commonly used in world-renowned traditional Indian home medicine system. Roots of Ashwagandha have been traditionally known to possess a variety of therapeutic and health promoting potentials that have not been sufficiently supported by laboratory studies. Nevertheless, most, if not all, of the preventive and therapeutic potentials have been assigned to its bioactive components, steroidal alkaloids and lactones. In contrast to the traditional use of roots, we have been exploring bioactivities in leaves of Ashwagandha. Here, we report that the leaves possess higher content of active Withanolides, Withaferin-A (Wi-A) and Withanone (Wi-N), as compared to the roots. We also established, for the first time, hydroponic cultivation of Ashwagandha and investigated the effect of various cultivation conditions on the content of Wi-A and Wi-N by chemical analysis and bioassays. We report that the Withanone/Withaferin A-rich leaves could be obtained by manipulating light condition during hydroponic cultivation. Furthermore, we recruited cyclodextrins to prepare extracts with desired ratio of Wi-N and Wi-A. Hydroponically grown Ashwagandha and its extracts with high ratio of withanolides are valuable for cancer treatment.

Indexed as

Cell LineCell Line, TumorCell SurvivalChromatography, High Pressure LiquidEthanolHumansHydroponicsLightMedicine, AyurvedicPlant ExtractsPlant LeavesReproducibility of ResultsTime FactorsTriterpenesWithaniaWithanolidesAshwagandhaEthanolPlant ExtractsTriterpeneswithaferin AWithanolideswithanone

Identifiers

PMID27936030
PMCPMC5147857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.